FIELD: biochemistry.
SUBSTANCE: invention relates to biochemistry. Humanized antibody BAT-1 or its antigen-binding fragment are described, which have anti-tumor and immunostimulating activity, containing variable light chain domain, as shown in SEQ ID NO:1, where Phe97 is substituted by Ala, and variable heavy chain domain, as shown in SEQ ID NO:5, where Trp107 is substituted by Ala. Invention also describes polynucleotide coding described antibody, expression vector and host cell containing said polynucleotide. Use of above antibody for treating malignant tumor and immunodeficiency disorders in individual is described.
EFFECT: invention extends range of products for treating malignant tumors and immune disorders.
17 cl, 1 dwg, 2 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES AGAINST OX40 AND THEIR USE | 2017 |
|
RU2783314C2 |
| ANTIBODIES AGAINST HUMAN VSIG4 AND APPLICATION THEREOF | 2019 |
|
RU2776638C1 |
| ANTI-HUMAN 4-1BB ANTIBODIES AND USE THEREOF | 2018 |
|
RU2725811C1 |
| ANTIBODIES AGAINST HUMAN 4-1BB AND THEIR USE | 2018 |
|
RU2777573C2 |
| ANTIBODIES TO PROTEIN CD38, AND THEIR USE | 2019 |
|
RU2776795C2 |
| TREATING CANCER WITH COMBINATION OF PD-1 ANTAGONIST AND DINACICLIB | 2014 |
|
RU2705795C2 |
| ANTIBODY AGAINST MUC1 | 2019 |
|
RU2792347C2 |
| AIMED AT UPARAP ANTIBODY-DRUG CONJUGATES | 2017 |
|
RU2740311C2 |
| ANTIBODIES AGAINST CD40 AND THEIR USE | 2018 |
|
RU2796413C2 |
| ANTI-SIRPα ANTIBODY AND USE THEREOF | 2021 |
|
RU2822496C1 |
